IBRXImmunityBio, Inc.
What is the market doing?
No clear lean: in an uptrend, but heavily shorted (+12% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +50% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How IBRX is trading
ImmunityBio, Inc. is +285% over the past year while the S&P 500 is +18%: 267 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +50%
vs 200-day average · a clear uptrend
- RSI (14)
- 69
RSI (14) · neutral
- Below its 52-week high
- 9.0%
Below its 52-week high
Details›
- Last close2026-10-09
- $10.51
- 1 monthS&P 500 +2.7%
- +36%
- 1 yearS&P 500 +18%
- +285%
- 5 yearsS&P 500 +88%
- +12%
- vs 50-day average$8.27
- +27%
- 52-week high
- $11.55
- 52-week low
- $1.98
- Annualised volatility
- 102%
| Year | Return |
|---|---|
| 2026 (year to date) | +431% |
| 2025 | −23% |
| 2024 | −49% |
| 2023 | −0.99% |
| 2022 | −17% |
| 2021 | −54% |
| 2020 | +252% |
| 2019 | +227% |
| 2018 | −74% |
| 2017 | −22% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +28% |
| Feb | 10 | 6 of 10 | +12% |
| Mar | 10 | 2 of 10 | −12% |
| Apr | 10 | 4 of 10 | +1.3% |
| May | 10 | 5 of 10 | +6.8% |
| Jun | 10 | 4 of 10 | +15% |
| Jul | 11 | 4 of 11 | −3.6% |
| Aug | 11 | 4 of 11 | −5.7% |
| Sep | 11 | 5 of 11 | +1.3% |
| Oct | 11 | 5 of 11 | +3.7% |
| Nov | 10 | 6 of 10 | +9.7% |
| Dec | 10 | 3 of 10 | +4.8% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.